Magnesium sulfate paste

Pays: Royaume-Uni

Langue: anglais

Source: MHRA (Medicines & Healthcare Products Regulatory Agency)

Ingrédients actifs:

Magnesium sulfate dried; Glycerol; Phenol

Disponible depuis:

Alliance Healthcare (Distribution) Ltd

Code ATC:

D11AX05

DCI (Dénomination commune internationale):

Magnesium sulfate dried; Glycerol; Phenol

Dosage:

450mg/1gram ; 550mg/1gram ; 5mg/1gram

forme pharmaceutique:

Cutaneous paste

Mode d'administration:

Cutaneous

classe:

No Controlled Drug Status

Type d'ordonnance:

Valid as a prescribable product

Descriptif du produit:

BNF: 13100500

Résumé des caractéristiques du produit

1.
TRADE NAME OF THE MEDICINAL PRODUCT
Magnesium Sulfate Paste BP
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Name of ingredient
Quantity
Dried Magnesium Sulfate
47. 762g
Phenol
0.497g
For the full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Paste.
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
As an adjunct to the management of superficial skin infections,
including boils.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
Adults, elderly and children
Apply to the affected area as required. There is no difference in the
quantity required for
affected areas or for children, adults or the elderly.
Stir well before use and apply liberally to the affected area.
Cover with a dressing.
Method of Administration
For topical application
4.3
CONTRAINDICATIONS
Hypersensitivity to the active substance or to any of the excipients
listed in section 6.1
4.4
SPECIAL WARNINGS AND PRECAUTIONS FOR USE
For external use only.
Do not use repeatedly.
4.5.
INTERACTIONS WITH OTHER MEDICAMENTS AND OTHER FORMS OF INTERACTION
No significant clinical interactions known.
4.6
FERTILITY, PREGNANCY AND LACTATION
As with all medicines it may be used during this period if the
benefits outweigh the risks.
4.7.
EFFECTS ON ABILITY TO DRIVE AND USE MACHINES
Not applicable.
4.8
UNDESIRABLE EFFECTS
None known
REPORTING OF SUSPECTED ADVERSE REACTIONS
Reporting suspected adverse reactions after authorisation of the
medicinal product is
important. It allows continued monitoring of the benefit/risk balance
of the medicinal product.
Healthcare professionals are asked to report any suspected adverse
reactions via the Yellow
Card Scheme at: www.mhra.gov.uk/yellowcard
4.9.
OVERDOSE
Should accidental ingestion occur, treat symptomatically.
5
PHARMACOLOGICAL PROPERTIES
5.1
PHARMACODYNAMIC PROPERTIES
Pharmacotherapeutic Group: Other Dermatologicals, Magnesium Sulfate
ATC code: D11A X05
Topical application of the ingredients of the paste help to draw
infected wounds and
reduce inflammation.
5.2.
PHARMACOKINETIC PROPERTIES
Not applicable.
5.3.
PRE